Non-compliance with the initial screening exam visit in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial

作者：Marcus Pamela M^*; Ogden Sheryl L; Gren Lisa H; Childs Jeffery C; Pretzel Shannon M; Lamerato Lois E; Walsh Kayo; Rozjabek Heather M; Mabie Jerome; Thomas Brett; Riley Tom

来源：Preventive Medicine, 2014, 67: 82-88.

DOI：10.1016/j.ypmed.2014.07.013

• Mass screening
• Adherence
• Compliance
• Cancer
• Randomized controlled trial as subject

Objective. Identify predictors of non-compliance with first round screening exams in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. %26lt;br%26gt;Method. The PLCO was conducted from 1993 to 2011 at 10 US institutions. A total of 154,897 healthy men and women ages 55-74 years were randomized. Intervention arm participants were invited to receive gender-appropriate screening exams for prostate, lung, colorectal and ovarian cancer. Using intervention-arm data (73,036 participants), non-compliance percentages for 13 covariates were calculated, as were unadjusted and adjusted odds ratios (ORs), and 95% confidence intervals. Covariates included demographic factors as well as factors specific to PLCO (e.g., method of consent, distance from screening center). %26lt;br%26gt;Results. The rate of non-compliance was 11% overall but varied by screening center. Significant associations were observed for most covariates but indicated modest increases or decreases in odds. An exception was the use of a two-step consent process (consented intervention arm participants for exams after randomization) relative to a one-step process (consented all participants prior to randomization) (OR: 2.2, 95% CI: 2.0-2.5). Non-compliance percentages increased with further distance from screening centers, but ORs were not significantly different from 1. %26lt;br%26gt;Conclusions. Many factors modestly influenced compliance. Consent process was the strongest predictor of compliance. Published by Elsevier Inc.

• 出版日期2014-10